[go: up one dir, main page]

WO2024258949A3 - Immunosorbent nanoparticles and methods of using thereof - Google Patents

Immunosorbent nanoparticles and methods of using thereof Download PDF

Info

Publication number
WO2024258949A3
WO2024258949A3 PCT/US2024/033583 US2024033583W WO2024258949A3 WO 2024258949 A3 WO2024258949 A3 WO 2024258949A3 US 2024033583 W US2024033583 W US 2024033583W WO 2024258949 A3 WO2024258949 A3 WO 2024258949A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunosorbent
nanoparticles
methods
microglobulin
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/033583
Other languages
French (fr)
Other versions
WO2024258949A2 (en
Inventor
Paul Moroz
Todd Yeates
Justin Miller
Roger CASTELLS-GRAELLS
Mark Aubrey ARBING
Aldo MUNOZ
Brian Thuan NGUYEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2024258949A2 publication Critical patent/WO2024258949A2/en
Publication of WO2024258949A3 publication Critical patent/WO2024258949A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Disclosed herein are immunosorbent nanoparticles, devices, and methods for selective removal of a target protein such as beta-2 microglobulin (B2M) from a liquid such as blood.
PCT/US2024/033583 2023-06-16 2024-06-12 Immunosorbent nanoparticles and methods of using thereof Pending WO2024258949A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508514P 2023-06-16 2023-06-16
US63/508,514 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024258949A2 WO2024258949A2 (en) 2024-12-19
WO2024258949A3 true WO2024258949A3 (en) 2025-02-13

Family

ID=93852878

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/033583 Pending WO2024258949A2 (en) 2023-06-16 2024-06-12 Immunosorbent nanoparticles and methods of using thereof

Country Status (1)

Country Link
WO (1) WO2024258949A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002278A1 (en) * 1994-07-18 1996-02-01 Laboratoires Upsa Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies
US20110020311A1 (en) * 2009-07-27 2011-01-27 James Layne Boucher Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy
US20130118979A1 (en) * 2007-12-03 2013-05-16 Hepa Wash Gmbh Dialysate Regeneration Unit
US20150356240A1 (en) * 2013-02-07 2015-12-10 University of Washington Through it's Center for Commercialization Self-Assembling Protein Nanostructures
US20220062430A1 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Self Assembling Protein Nanoparticles as Carrier Molecules

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002278A1 (en) * 1994-07-18 1996-02-01 Laboratoires Upsa Immunonanoparticles coated with anti-beta-2 microglobulin monoclonal antibodies
US20130118979A1 (en) * 2007-12-03 2013-05-16 Hepa Wash Gmbh Dialysate Regeneration Unit
US20110020311A1 (en) * 2009-07-27 2011-01-27 James Layne Boucher Therapy of multiple sclerosis, inflammatory neurological diseases and neurodegenerative diseases with 5'-deoxyadenosylcobalamin, growth hormone, immunomodulators, interleukins, other therapeutic agents, and physiotherapy
US20150356240A1 (en) * 2013-02-07 2015-12-10 University of Washington Through it's Center for Commercialization Self-Assembling Protein Nanostructures
US20220062430A1 (en) * 2020-08-25 2022-03-03 The Regents Of The University Of California Self Assembling Protein Nanoparticles as Carrier Molecules

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MCNULTY MATTHEW J., SCHWARTZ ANTON, DELZIO JESSE, KARUPPANAN KALIMUTHU, JACOBSON AARON, HART OLIVIA, DANDEKAR ABHAYA, GIRITCH ANAT: "Affinity Sedimentation and Magnetic Separation With Plant-Made Immunosorbent Nanoparticles for Therapeutic Protein Purification", FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, FRONTIERS RESEARCH FOUNDATION, CH, vol. 10, CH , XP093280477, ISSN: 2296-4185, DOI: 10.3389/fbioe.2022.865481 *

Also Published As

Publication number Publication date
WO2024258949A2 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
AU2003214752A1 (en) Method and device for the removal of partially protein bound substances
WO2004113922A3 (en) System and method employing photokinetic techniques in cell biology imaging applications
WO2018056821A8 (en) Binding molecules that modulate a biological activity expressed by a cell
WO2005000095A3 (en) Isoforms of brain natriuretic peptide
WO2000059380A3 (en) Apparatus and methods for anastomosis
WO2022175414A8 (en) Multispecific anti-tcr delta variable 1 antibodies
EP1479794A3 (en) Apparatus and method for growing crystal, and apparatus and method for analysing crystal
WO2024258949A3 (en) Immunosorbent nanoparticles and methods of using thereof
WO2004047753A3 (en) Freeze-drying microscope stage apparatus and process of using the same
WO2024163634A3 (en) Methods and devices for manipulating biological samples
WO2005118885A3 (en) Methods and apparatus for detection of viral infection
WO2023146922A3 (en) Methods for human leukocyte antigen typing and phasing
EP4273161A4 (en) Protein containing heterodimer antibody fc, and preparation method therefor
EP4269615A4 (en) Biochip for spatial transcriptomic analysis, manufacturing method therefor and application thereof
WO2022164989A3 (en) Microfluidics systems, devices, and methods
WO2021262012A3 (en) Protein scaffold
WO2006106400A3 (en) Capsules containing seminal material for artificial insemination
EP1710562A3 (en) Microfluidic system and method of utilization
WO2024243043A3 (en) Continuous purification device
WO2004011401A3 (en) Method for making biochips
WO2022047176A3 (en) Single-chain coronavirus viral membrane protein complexes
GB2605887A (en) Controlled chemical synthesis using polymer substrates and nanofluidic separation systems
WO2025186168A8 (en) A gas membrane device
AU2024322991A1 (en) Anti-a-beta protein antibodies, methods and uses thereof
NO20055948L (en) Purification of HER-2 variants